Trial Watch: Dendritic Cell Vaccination for Cancer Immunotherapy

Overview

Journal Oncoimmunology

Specialty Allergy & Immunology

Date 2019 Oct 25

PMID 31646087

Citations 81

Authors

Jenny Sprooten

Jolien Ceusters

An Coosemans

Patrizia Agostinis

Steven de Vleeschouwer

Laurence Zitvogel

Guido Kroemer

Lorenzo Galluzzi

Abhishek D Garg

Affiliations

Soon will be listed here.

Abstract

Dendritic- cells (DCs) have received considerable attention as potential targets for the development of anticancer vaccines. DC-based anticancer vaccination relies on patient-derived DCs pulsed with a source of tumor-associated antigens (TAAs) in the context of standardized maturation-cocktails, followed by their reinfusion. Extensive evidence has confirmed that DC-based vaccines can generate TAA-specific, cytotoxic T cells. Nonetheless, clinical efficacy of DC-based vaccines remains suboptimal, reflecting the widespread immunosuppression within tumors. Thus, clinical interest is being refocused on DC-based vaccines as combinatorial partners for T cell-targeting immunotherapies. Here, we summarize the most recent preclinical/clinical development of anticancer DC vaccination and discuss future perspectives for DC-based vaccines in immuno-oncology.

Citing Articles

Advancing Cancer Therapy: The Role of KIF20A as a Target for Inhibitor Development and Immunotherapy.

Moon D Cancers (Basel). 2024; 16(17).

PMID: 39272816 PMC: 11393963. DOI: 10.3390/cancers16172958.

Integration of the PD-L1 inhibitor atezolizumab and WT1/DC vaccination into standard-of-care first-line treatment for patients with epithelioid malignant pleural mesothelioma-Protocol of the Immuno-MESODEC study.

Van den Bossche J, De Laere M, Deschepper K, Germonpre P, Valcke Y, Lamont J PLoS One. 2024; 19(7):e0307204.

PMID: 39008481 PMC: 11249236. DOI: 10.1371/journal.pone.0307204.

Clinical application of immunogenic cell death inducers in cancer immunotherapy: turning cold tumors hot.

Han Y, Tian X, Zhai J, Zhang Z Front Cell Dev Biol. 2024; 12:1363121.

PMID: 38774648 PMC: 11106383. DOI: 10.3389/fcell.2024.1363121.

Checkpoint inhibitor-expressing lentiviral vaccine suppresses tumor growth in preclinical cancer models.

Tada T, Norton T, Leibowitz R, Landau N J Immunother Cancer. 2024; 12(4).

PMID: 38658032 PMC: 11043704. DOI: 10.1136/jitc-2023-008761.

Adjuvant Wilms' tumour 1-specific dendritic cell immunotherapy complementing conventional therapy for paediatric patients with high-grade glioma and diffuse intrinsic pontine glioma: protocol of a monocentric phase I/II clinical trial in Belgium.

Van Genechten T, De Laere M, Van den Bossche J, Stein B, De Rycke K, Deschepper C BMJ Open. 2024; 14(3):e077613.

PMID: 38503417 PMC: 10952861. DOI: 10.1136/bmjopen-2023-077613.

References

Zitvogel L, Mayordomo J, Tjandrawan T, DeLeo A, Clarke M, Lotze M . Therapy of murine tumors with tumor peptide-pulsed dendritic cells: dependence on T cells, B7 costimulation, and T helper cell 1-associated cytokines. J Exp Med. 1996; 183(1):87-97. PMC: 2192415. DOI: 10.1084/jem.183.1.87. View

Schreibelt G, Bol K, Westdorp H, Wimmers F, Aarntzen E, Duiveman-de Boer T . Effective Clinical Responses in Metastatic Melanoma Patients after Vaccination with Primary Myeloid Dendritic Cells. Clin Cancer Res. 2015; 22(9):2155-66. DOI: 10.1158/1078-0432.CCR-15-2205. View

Yu H, Tian Y, Wang Y, Mineishi S, Zhang Y . Dendritic Cell Regulation of Graft-Vs.-Host Disease: Immunostimulation and Tolerance. Front Immunol. 2019; 10:93. PMC: 6367268. DOI: 10.3389/fimmu.2019.00093. View

Boczkowski D, Nair S, Snyder D, Gilboa E . Dendritic cells pulsed with RNA are potent antigen-presenting cells in vitro and in vivo. J Exp Med. 1996; 184(2):465-72. PMC: 2192710. DOI: 10.1084/jem.184.2.465. View

Mastelic-Gavillet B, Balint K, Boudousquie C, Gannon P, Kandalaft L . Personalized Dendritic Cell Vaccines-Recent Breakthroughs and Encouraging Clinical Results. Front Immunol. 2019; 10:766. PMC: 6470191. DOI: 10.3389/fimmu.2019.00766. View

Dematos P, Vervaert C, Hester D, Seigler H . Pulsing of dendritic cells with cell lysates from either B16 melanoma or MCA-106 fibrosarcoma yields equally effective vaccines against B16 tumors in mice. J Surg Oncol. 1998; 68(2):79-91. DOI: 10.1002/(sici)1096-9098(199806)68:2<79::aid-jso3>3.0.co;2-h. View

Nair S, Snyder D, Rouse B, Gilboa E . Regression of tumors in mice vaccinated with professional antigen-presenting cells pulsed with tumor extracts. Int J Cancer. 1997; 70(6):706-15. DOI: 10.1002/(sici)1097-0215(19970317)70:6<706::aid-ijc13>3.0.co;2-7. View

Wan Y, Bramson J, Carter R, Graham F, Gauldie J . Dendritic cells transduced with an adenoviral vector encoding a model tumor-associated antigen for tumor vaccination. Hum Gene Ther. 1997; 8(11):1355-63. DOI: 10.1089/hum.1997.8.11-1355. View

Dudek A, Martin S, Garg A, Agostinis P . Immature, Semi-Mature, and Fully Mature Dendritic Cells: Toward a DC-Cancer Cells Interface That Augments Anticancer Immunity. Front Immunol. 2013; 4:438. PMC: 3858649. DOI: 10.3389/fimmu.2013.00438. View

10.

Vanpouille-Box C, Demaria S, Formenti S, Galluzzi L . Cytosolic DNA Sensing in Organismal Tumor Control. Cancer Cell. 2018; 34(3):361-378. DOI: 10.1016/j.ccell.2018.05.013. View

11.

Sistigu A, Yamazaki T, Vacchelli E, Chaba K, Enot D, Adam J . Cancer cell-autonomous contribution of type I interferon signaling to the efficacy of chemotherapy. Nat Med. 2014; 20(11):1301-9. DOI: 10.1038/nm.3708. View

12.

Mikyskova R, Indrova M, Stepanek I, Kanchev I, Bieblova J, Vosahlikova S . Dendritic cells pulsed with tumor cells killed by high hydrostatic pressure inhibit prostate tumor growth in TRAMP mice. Oncoimmunology. 2017; 6(12):e1362528. PMC: 5706615. DOI: 10.1080/2162402X.2017.1362528. View

13.

Nussenzweig M, Mellman I . Ralph Steinman (1943-2011). Nature. 2011; 478(7370):460. DOI: 10.1038/478460a. View

14.

Kong B, Bolton H, Kim J, Silveira P, Fromm P, Clark G . On the Other Side: Manipulating the Immune Checkpoint Landscape of Dendritic Cells to Enhance Cancer Immunotherapy. Front Oncol. 2019; 9:50. PMC: 6372550. DOI: 10.3389/fonc.2019.00050. View

15.

Jiang N, Qiao G, Wang X, Morse M, Gwin W, Zhou L . Dendritic Cell/Cytokine-Induced Killer Cell Immunotherapy Combined with S-1 in Patients with Advanced Pancreatic Cancer: A Prospective Study. Clin Cancer Res. 2017; 23(17):5066-5073. DOI: 10.1158/1078-0432.CCR-17-0492. View

16.

Berraondo P, Sanmamed M, Ochoa M, Etxeberria I, Aznar M, Perez-Gracia J . Cytokines in clinical cancer immunotherapy. Br J Cancer. 2018; 120(1):6-15. PMC: 6325155. DOI: 10.1038/s41416-018-0328-y. View

17.

Venkateswaran K, Verma A, Bhatt A, Shrivastava A, Manda K, Raj H . Emerging Roles of Calreticulin in Cancer: Implications for Therapy. Curr Protein Pept Sci. 2017; 19(4):344-357. DOI: 10.2174/1389203718666170111123253. View

18.

Adotevi O, Vingert B, Freyburger L, Shrikant P, Lone Y, Quintin-Colonna F . B subunit of Shiga toxin-based vaccines synergize with alpha-galactosylceramide to break tolerance against self antigen and elicit antiviral immunity. J Immunol. 2007; 179(5):3371-9. DOI: 10.4049/jimmunol.179.5.3371. View

19.

Pol J, Vacchelli E, Aranda F, Castoldi F, Eggermont A, Cremer I . Trial Watch: Immunogenic cell death inducers for anticancer chemotherapy. Oncoimmunology. 2015; 4(4):e1008866. PMC: 4485780. DOI: 10.1080/2162402X.2015.1008866. View

20.

Miwa S, Nishida H, Tanzawa Y, Takeuchi A, Hayashi K, Yamamoto N . Phase 1/2 study of immunotherapy with dendritic cells pulsed with autologous tumor lysate in patients with refractory bone and soft tissue sarcoma. Cancer. 2017; 123(9):1576-1584. DOI: 10.1002/cncr.30606. View